Last week we attended the AACR Annual Meeting in Orlando. We had lots of interesting conversations, discussed great science and experienced plenty of traffic at the poster presentations. If you are interested in the data, please reach out to Fabian Pruissen, Business Developer, to learn more about the work presented. Below you find a short description of the two posters.

Radioresistant prostate cancer PDX model

We developed and characterized a radioresistant PSMA positive patient derived xenograft (PDX) prostate tumor model. Radioresistance was induced by external beam radiation and resistance was maintained after passage of the model. The radioresistant tumor is resistant towards Lu177-PSMA-617 (see figure below) while the tumor uptake and growth is unaffected. Initial results indicate that Olaparib re-sensitizes the tumors to Lu177-PSMA-617 therapy.

Tumor growth after single dose of 30MBq Lu177-PSMA-617.

Tumor growth after single dose of 30MBq Lu177-PSMA-617.

Intracranial breast cancer brain metastases models

Stereotactic inoculation of breast cancer cells into the brain is the most employed method for establishing orthotopic breast cancer brain metastases (BCBM). This method is highly reproducible but the resulting tumor lacks several of the critical characteristics of BCBM such as extravasation and micro seeding. Furthermore, the inoculation method results in gross manipulation of brain tissue which could lead to irreversible damage on the blood brain barrier (BBB). We have developed an intracarotid model resembling BCBM observed in the clinic, where extravasation of cancer cells into the brain leads to the establishment of multiple metastases through micro seeding. We compared tumor establishment as well as BBB integrity between the two models using bioluminescence imaging, MR imaging and performed histological assessment of isolated brain tissue.

We look forward to continuing the work presented. Follow us on LinkedIn to stay updated.